#USA #Rochester #Mu Medical #Bedo Solutions #Viseon Labs

Mu Medical: A Paradigm Shift in Eyecare

Mu Medical, formerly known as Nanodropper, recently announced an exciting partnership with Bedo Solutions and Viseon Labs. This collaboration aims to transform the landscape of eyecare, building a comprehensive platform that leverages advanced artificial intelligence (AI) and precision engineering.

The Future of Eyecare

Nanodropper has historically led the market in micro-volume ophthalmic delivery, but this latest announcement marks a significant milestone in the company's evolution. The integration of Bedo Solutions and Viseon Labs will allow Mu Medical to expand its offerings from a single-product device to a more holistic medtech ecosystem.

Dr. Allisa Song, the visionary Founder and CEO of Nanodropper, expressed her commitment to redefining how eyecare is approached. Traditional eyecare has often relied on standardized drop sizes and static treatment protocols. Mu Medical aims to change this paradigm by personalizing patient care through innovative technologies.

Uniting Under a Shared Vision

All three companies—Nanodropper, Bedo Solutions, and Viseon Labs—were founded by physicians who are dedicated to improving patient access and outcomes. This shared medical background strongly influences their collective approach to innovation. By merging their expertise, the alliance enhances ophthalmic care with a focus on meaningful therapeutic results.

The leadership structure of Mu Medical will include Dr. Allisa Song as CEO and Board Chair, Dr. Sina Fateh as Chief Strategy Officer, and Dr. Robert Kinast as Medical Advisor and Board Observer. This collaboration between experts assures stakeholders of a strong medical lens guiding the development of new solutions.

A Comprehensive Product Portfolio

Once the proposed transactions are finalized, Mu Medical plans to streamline its offerings into four distinct categories:
1. Consumer Devices: Featuring products like the Nanodropper® Adaptor and GentleDrop®, which are designed for optimized patient use.
2. Primary Packaging: Including innovations such as MuPACK-JT2™ and MuVEYE™, which promise precision dosing directly at the source.
3. Monitoring Solutions: The VuTRACK™ system uses machine vision technology for tracking patient adherence, generating actionable health insights.
4. AI Therapeutics: Products like Myopia AI™ and VizGuard™ harness advanced analytics to provide personalized treatment recommendations.

These categories combine to create an integrated approach that modernizes treatment delivery and monitoring in ophthalmology.

Bringing the Vision to Life

Mu Medical's debut at the 44th Annual J.P. Morgan Healthcare Conference week will showcase the company's vision and the innovations it brings to the medtech community. Scheduled for January 12-15, 2026, in San Francisco, this presentation highlights the company's commitment to enhancing precision and personalized eyecare.

About Mu Medical

Mu Medical stands as a testament to the power of collaboration in healthcare. By integrating its strengths with those of Bedo Solutions and Viseon Labs, the company aims to drive advancements in drug delivery, home monitoring, and AI-driven clinical insights.

For more information about the upcoming transformations in eyecare, visit www.mumedical.com.

Forward-Looking Statements

This announcement includes forward-looking statements about future collaborations and product offerings. The completion of these transactions is subject to customary closing conditions. As with any business initiative, actual outcomes may differ from the projections discussed today.